pages/clinical.md
... ...
@@ -6,13 +6,15 @@ link-citations: true
6 6
7 7
# Clinical relevance
8 8
9
-|Gene|Status|Type|Entity|Therapy|Biomarker?|
9
+## Therapeutic targets
10
+
11
+|Gene|Status|Entity|Therapy|Biomarker?|
10 12
|-|-|-|-|
11
-|[BCL2](/BCL2)|not approved|therapeutic target|DLBCL|venetoclax|Not applicable|
12
-|[BTK](/BTK#clinical-relevance)|not approved|therapeutic target|DLBCL|ibrutinib|ABC gene expression signature, MCD genetic subgroup|
13
-|[CD79B](/CD79B#clinical-relevance)|FDA approved|therapeutic target|DLBCL|polatuzumab vedotin|ABC gene expression signature|
14
-|[EZH2](/EZH2#clinical-relevance)|FDA approved|therapeutic target|FL|tazemetostat|Mutation|
15
-|[XPO1](/XPO1#clinical-relevance)|FDA approved|therapeutic target|DLBCL|selinexor|Not applicable|
13
+|[BCL2](/BCL2)|not approved|DLBCL|venetoclax|Not applicable|
14
+|[BTK](/BTK#clinical-relevance)|not approved|DLBCL|ibrutinib|ABC gene expression signature, MCD genetic subgroup|
15
+|[CD79B](/CD79B#clinical-relevance)|FDA approved|DLBCL|polatuzumab vedotin|ABC gene expression signature|
16
+|[EZH2](/EZH2#clinical-relevance)|FDA approved|FL|tazemetostat|Mutation|
17
+|[XPO1](/XPO1#clinical-relevance)|FDA approved|DLBCL|selinexor|Not applicable|
16 18
17 19
18 20
## References